2384results about "Other foreign material introduction processes" patented technology

Disclosed herein are engineered rhizobia having nif clusters that enable the fixation of nitrogen under free-living conditions, as well as ammonium and oxygen tolerant nitrogen fixation under free-living conditions. Also provided are methods for producing nitrogen for consumption by a cereal crop using these engineered rhizobia.

The invention relates to a high-activity recombinant XVII type collagen as well as a rapid preparation method and application thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the high-activity recombinant XVII type collagen is as shown in SEQ ID NO. 1, and the nucleotide sequence of the high-activity recombinant XVII type collagen is as shown in SEQ ID NO. 2. The invention also provides a preparation method and application of the recombinant XVII type collagen. The high-activity recombinant XVII type collagen has good biological activity, has good effects of promoting cell adhesion, cell proliferation and cell migration, and can be compounded with other proteins to form raw materials of tissue engineering products, cosmetics, health care products or medicines. The high-activity recombinant XVII type collagen gene is integrated to different positions of a yeast genome through three different vectors, and the copy number of a target gene is increased, so that the expression quantity of the recombinant XVII type collagen is remarkably increased, and the yield of the high-activity recombinant XVII type collagen is effectively increased.

The present disclosure relates to systems, devices, and methods for electroporating. In an embodiment, the present disclosure relates to an electroporation system, comprising at least one electroporation chamber, each electroporation chamber comprising a first electrode and a second electrode, a plurality of ports comprising an inlet port at a first portion of each electroporation chamber, and an outlet port at a second portion of each electroporation chamber, a fluid conduit arranged between the first electrode and the second electrode, the fluid conduit being in fluid communication with the inlet port and the outlet port, and an automated system for electroporation operatively connected to the first electrode and the second electrode of the at least one electroporation chamber.

The invention discloses a method for improving beef quality, an action mechanism and an experimental method, in a cattle body, vitamin A can activate the expression of EBF2 through an active metabolite RA of the vitamin A, and the EBF2 can inhibit the transcription process of CYP26B1 in a targeted manner to maintain the activity of a retinol signal channel, so that PPAR gamma and downstream lipid metabolism related genes thereof are activated, and the activity of the retinol signal channel is improved. Fatty acid transport and lipid accumulation in fat cells in the cattle muscle are promoted, fat deposition in the cattle muscle is promoted, and the beef quality is improved. By constructing the molecular network for regulating and controlling the formation of the fat in the cattle muscle, a complex regulation and control mechanism for controlling the fat deposition in the cattle muscle can be understood more deeply, a method for improving the beef quality based on regulating and controlling the vitamin A mediated key factor EBF2 is provided, and a new way is provided for improving the beef quality in a targeted manner.

The invention discloses a cherax quadricarinatus oocyte targeted penetrating peptide VgSP and a living body delivery method thereof, and belongs to the technical field of biology. The invention provides the cherax quadricarinatus oocyte targeted penetrating peptide VgSP on one hand, and provides application of the cherax quadricarinatus oocyte targeted penetrating peptide VgSP on the other hand. The invention provides a polypeptide VgSP capable of being recognized by a cherax quadricarinatus oocyte surface receptor and mediated into an oocyte, and an injection and detection method of the polypeptide in sub-adult and adult female cherax quadricarinatus. The breakthrough lays a technical foundation for establishing a gene editing element delivery method with oocyte targeting, and is expected to be applied to the field of cherax quadricarinatus gene editing.

The invention discloses a target segment for preventing and treating tomato brown fruit wrinkling virus in tobacco, double-stranded RNA (Ribonucleic Acid) and application of the target segment and the double-stranded RNA. Wherein the nucleotide sequence of the target segment is as shown in SEQ ID NO.3, or a sequence which is as shown in SEQ ID NO.3, has at least 90% of homology and has coded amino acid as shown in SEQ ID NO.4 is substituted. The invention also discloses a double-stranded RNA of a targeted interference target section, and the double-stranded RNA can significantly inhibit the proliferation of the tomato brown crinkled fruit virus in tobacco by injecting or smearing tobacco leaves, so that the double-stranded RNA can be effectively applied to prevention and control of tobacco diseases caused by the tomato brown crinkled fruit virus. The method for preventing and controlling the tomato brown crinkled fruit virus in the tobacco by using the double-stranded RNA is safe, harmless and efficient, and provides a new path for preventing and controlling plant virus diseases by using RNAi (Ribonucleic Acid Interference).

Among other things, the present disclosure provides oligonucleotides, compositions and methods thereof that can bring about specific editing of a target adenosine in a target RNA molecule. Such oligonucleotides, compositions and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders, diseases and syndromes that can benefit from adenosine modification.

Disclosed herein are engineered rhizobia having nif clusters that enable the fixation of nitrogen under free-living conditions, as well as ammonium and oxygen tolerant nitrogen fixation under free-living conditions. Also provided are methods for producing nitrogen for consumption by a cereal crop using these engineered rhizobia.

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).

The present disclosure provides storage stable solid compositions including a biopharmaceutical agent and a polyacrylamide-based copolymer. The inventors have demonstrated that particular polyacrylamide-based copolymers can be used as stabilizing excipients in lyophilized formulations of biopharmaceutical agents. Also provided are methods of reconstituting and using the compositions, including methods of administering the reconstituted composition to a human subject in need thereof via injection, e.g., subcutaneous injection.

The present invention relates to peptides, in particular cell-penetrating peptides, and to conjugates of such cell-penetrating peptides with a therapeutic molecule. The present invention further relates to use of such peptides or conjugates in methods of treatment or as a medicament, especially in the treatment of genetic disorders and in particular muscular dystrophies such as Duchenne muscular dystrophy.

The invention relates to the field of biological medicine, in particular to elastin-like polypeptide as well as a preparation method and application thereof. The amino acid sequence of the elastin-like polypeptide is (VPGXG) n, X comprises I, A and F, and n is an integer selected from 20-120. The elastin-like polypeptide disclosed by the invention has reversible phase change temperature, a purification method is simple, and the elastin-like polypeptide has good and controllable release capacity. The elastin-like polypeptide disclosed by the invention can serve as a drug storage cavern, can be coupled with various drugs, and can improve the treatment effect of the carried drugs, so that targeted therapy is more accurate.

The invention belongs to the technical field of biology, and provides an electroporation buffer solution applied to exosome electroporation, the pH value is 6.8-9.8, the osmotic pressure is 80-320 mosm, water is used as a solvent, and the electroporation buffer solution comprises the following components: 15-25% w / v of iodixanol, 1.035-1.265 mM of KH2PO4, 22.5-27.5 mM of KCl, 0.18-0.22 mM of EDTA-2Na and 18-22 mM of HEPES. The electroporation buffer solution provided by the invention can improve the loading efficiency of the load and reduce damage to an exosome membrane structure and internal bioactive molecules in an electroporation process. The electroporation buffer solution can effectively reduce aggregation and fusion phenomena of exosomes after electroporation, and improves the stability and integrity of the exosomes. The electroporation buffer solution provided by the invention can improve the application degree of the exosome as a targeting drug delivery system.

Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.

The invention discloses an interfering RNA (Ribonucleic Acid) for inhibiting a PCSK9 gene and application of the interfering RNA. The interfering RNA comprises any one or more than two nucleotide sequences as shown in SEQ ID NO: 1-40 and SEQ ID NO: 73-96. The interfering RNA can better target and silence mRNA of the liver PCSK9, reduce the protein level of the PCSK9, enhance LDL-C metabolism and reduce serum cholesterol, and a solid technical basis is provided for research and development of siRNA drugs for prevention and treatment of PCSK9 gene mediated diseases and symptom relief.

Provided are methods, compositions, and kits for improving a delivery of a nucleic acid to a cell in an organ of a subject. Such methods, compositions, and kits may include a sonoactive agent and a nucleic acid comprising a cargo polynucleotide and a nuclear localization element and / or an innate immune response avoidance moiety, which may be an aptamer. Delivery may involve sonoporation.

The invention provides a method for delivering double-stranded RNA (Ribonucleic Acid) molecules into locusts through epidermis, a product and application. The method provided by the invention comprises the following steps: mixing double-stranded RNA molecules to be delivered with a polymer carrier as shown in a formula 1 to obtain a mixture of the double-stranded RNA molecules and the polymer carrier; adding a surfactant into the mixture of the double-stranded RNA molecules and the polymer carrier to obtain a delivery mixture; the delivery mixture is contacted with the epidermis of the locust, so that the double-stranded RNA molecule enters the locust body through the epidermis. According to the method provided by the invention, the double-stranded RNA molecules can penetrate through relatively thick epidermis to enter the locust body, so that the stability of the double-stranded RNA molecules in the locust body is improved, and efficient gene interference is realized. The method provided by the invention can be used for research of locust gene functions and application of RNA pesticides.

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

The invention relates to the technical field of microorganisms, in particular to a bacterial strain for producing cholest-5, 7, 24-triene-3beta alcohol and application of the bacterial strain. The invention provides a gene engineering strain for producing cholest-5, 7, 24-triene-3 beta alcohol, an ERG4 gene, an ERG5 gene and an ERG6 gene are knocked out, and the yield of the cholest-5, 7, 24-triene-3 beta alcohol of the strain reaches 360 mg / L and is increased by 300% or above compared with the prior art; in addition, the fermentation time is shortened to 20 hours, and compared with other strains, the fermentation time is saved by 70 hours.

The invention belongs to the field of biomedical materials, and particularly relates to a PBAE-DOPE-PEG2000 polymer-lipid nanocomposite and a preparation method and application thereof.The preparation method comprises the steps that a dimethyl sulfoxide-ethanol solution formed by mixing DOPE-PEG2000 lipid and PBAE serves as an oil phase, a sodium acetate / acetic acid buffer solution serves as a water phase, and the PBAE-DOPE-PEG2000 polymer-lipid nanocomposite is prepared through a microfluidic synthesis mode; the PBAE-DOPE-PEG2000 polymer-lipid nano composite material is prepared by the steps of carrying out ultrasonic treatment on the PBAE-DOPE-PEG The polymer-lipid nano composite material can efficiently load exogenous genes, the surface performance of the polymer-lipid nano composite material is changed and the stability of nano particles is improved by introducing DOPE-PEG2000 lipid, membrane fusion can be promoted, the risk of lysosome degradation is reduced, the transfection process of the exogenous genes in recipient cells is accelerated, and efficient expression in 293FT cells is realized. The efficient transfection of the polymer-lipid nanocomposite material is expected to show important application prospects in immune cell therapy or tumor cell therapy.

The invention belongs to the technical field of biological medicines, and particularly relates to a DNA tetrahedron capable of carrying oligonucleotides and nucleic acid analogues as well as a preparation method and application of the DNA tetrahedron. The method comprises the following steps: cutting off one single-chain DNA in classical tetrahedral framework nucleic acid to form three short-chain DNAs, and self-assembling six single-chain DNAs again to form a DNA tetrahedron to obtain ORT; according to the invention, the mismatching and self-matching phenomena of tFNA are improved, the yield of tFNA is improved, and the tFNA has good structural stability, high bioavailability and excellent biocompatibility; the ORT prepared by the invention can be used as a drug carrier for loading nucleic acid and nucleic acid analogues, protein drugs or small molecule drugs, and the application of the ORT in the aspects of drug delivery, gene therapy, biosensing and the like is promoted.

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

The invention relates to the technical field of animal gene engineering, in particular to an sgRNA guiding sequence of specific targeting pig HMGA1 and HMGA2 genes and application of the sgRNA guiding sequence. According to the invention, four sgRNA guiding sequences are respectively designed aiming at porcine HMGA1 and HMGA2 genes, and the sgRNA guiding sequences capable of efficiently targeting the porcine HMGA1 and HMGA2 genes and the combination of the sgRNA guiding sequences are selected from the four sgRNA guiding sequences by utilizing a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 system. The sgRNA guide sequence and the combination thereof provided by the invention are combined with a CRISPR / Cas9 system for use, so that the editing of the HMGA1 and HMGA2 genes in the pig can be realized, the simultaneous knockout of the HMGA1 and HMGA2 genes is further realized, and a technical foundation is laid for the application of gene breeding, xenotransplantation, gene function research models and the like.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).

The invention discloses a gene engineering exosome and a slow release method and application thereof, the gene engineering exosome is derived from human adipose-derived stem cells, si-tgfbr2 is loaded in the gene engineering exosome, the si-tgfbr2 is specific siRNA aiming at a Tgfbr2 gene, and the gene engineering exosome can regulate and control proliferation of VSMCs, inhibit transformation of the VSMCs from a contraction phenotype to a synthetic phenotype when the VSMCs are stimulated, and inhibit the growth of the VSMCs. According to the present invention, the gene engineering exosome can be used to maintain the normal structure and the function of the blood vessel, and the sustained release effect of the content in the gene engineering exosome can be achieved by wrapping the gene engineering exosome in the PHA biodegradable material, such that the local treatment concentration can be easily stabilized, the drug administration frequency can be easily reduced, the lasting time of the treatment effect can be easily prolonged, and the treatment gene can be effectively delivered to the target cell; the treatment effect is improved; when being used for modifying a small-caliber artificial blood vessel, the small-caliber artificial blood vessel can be improved in biocompatibility and functionality, and can be prevented from being implanted into the blood vessel for remodeling unbenign hyperplasia stenosis; the invention not only provides a new thought and method for the treatment of vascular diseases, but also has important clinical application value and popularization prospect.

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

The invention discloses an experimental method based on depletion-type nk cells as a lung cancer treatment target, and relates to the technical field of bioinformatics. Comprising the following steps: S1, data processing; s2, identification of cell subset characteristic genes and cell type annotation; s3, re-clustering the NK cells; s4, NK cell function annotation; s5, differential gene expression analysis; s6, analyzing the difference of activation and inhibition of receptor expression by the RGS1 + NK cells through single cells; s7, performing quasi-time sequence analysis; s8, carrying out cell culture and siRNA transfection; s9, detecting the expression condition of an NK92mi cell activated receptor after the RGS1 is knocked down; s10, carrying out a lactic dehydrogenase release experiment; s11, measuring the IFN-gamma content of the cell supernatant; and S12, virtual screening of drugs. Through analysis and experimental verification, the key function of RGS1 in NK cell depletion in lung cancer is disclosed, and a new and potential molecular target is provided for lung cancer treatment.

The invention belongs to the technical field of gene engineering, and discloses a CRISPR / Cas9 delivery system and application thereof. The CRISPR / Cas9 delivery system is obtained by loading the CRISPR / Cas9 system with the fluorinated polyethyleneimine, and the fluorinated polyethyleneimine can deliver the CRISPR / Cas9 carrier into cells, has excellent transmembrane delivery efficiency, and can efficiently mediate the CRISPR / Cas9 system to enter target cells. The CRISPR / Cas9 delivery system is applied to large-scale breeding of aquatic animals, the use safety is high, the biocompatibility is excellent, and the delivery system has excellent gene editing efficiency and has wide application prospects in the field of gene editing breeding.